小细胞内囊泡-脂质体融合纳米平台sIVs-LPs@Hes：雾化递送靶向肺部炎症微环境以改善ALI
Small intracellular vesicle-liposome fusogenic nanoplatform sIVs-LPs@Hes: Nebulized delivery targeting pulmonary inflammatory microenvironment to improve ALI.
摘要(中文译文)
急性肺损伤（ALI）及其更严重的形式急性呼吸窘迫综合征（ARDS）是死亡率很高的严重呼吸系统疾病，以过度炎症诱导的病理性肺损伤为特征。目前ALI的治疗策略有限；传统治疗伴随严重副作用且缺乏靶向疗效。橙皮素（Hes）是一种富含于柑橘类水果中的天然黄烷酮，展现出良好的抗炎潜力，但其进一步临床应用受到溶解性差和生物利用度低的阻碍。来源于间充质干细胞的小细胞内囊泡（sIVs）已被证明具有产量高、细胞摄取快和稳定性优良的优势。鉴于此，本研究构建了一种负载Hes的sIVs-脂质体纳米递送系统（sIVs-LPs@Hes），通过雾化吸入用于ALI的治疗。我们的研究结果显示，sIVs-LPs@Hes可被肺部高效吸收并持久滞留，且通过MCU-mCa-NF-κB通路抑制糖酵解、促进巨噬细胞M2极化、改善肺部炎症状态、减轻肺水肿并修复病理性肺损伤，发挥了更优的保护作用。总之，本研究不仅阐明了Hes的具体抗炎机制，还通过整合sIVs和脂质体的优势开发了一种新型复合纳米递送系统，从而为ALI提供了一种有前景的潜在治疗策略。
Abstract
Acute lung injury (ALI) and its more severe form, acute respiratory distress syndrome (ARDS), are severe respiratory diseases with a high mortality rate, characterized by pathological lung damage induced by excessive inflammation. Current therapeutic strategies for ALI are limited; conventional treatments are associated with severe side effects and lack targeted efficacy. Hesperetin(Hes)is a natural flavanone abundant in citrus fruits that exhibits promising anti-inflammatory potential, yet its further clinical application is hindered by poor solubility and low bioavailability. Small intracellular vesicles (sIVs) derived from mesenchymal stem cells have been demonstrated to possess the advantages of high yield, rapid cellular uptake and excellent stability. In view of this, the present study constructed a Hes-loaded sIVs-liposome nanodelivery system (sIVs-LPs@Hes) for the treatment of ALI via nebulized inhalation. Our findings revealed that sIVs-LPs@Hes could be efficiently absorbed and persistently retained in the lung, and it exerted a superior protective effect by inhibiting glycolysis through the MCU-mCa-NF-κB pathway, promoting M2 polarization of macrophages, ameliorating pulmonary inflammatory status, reducing pulmonary edema and repairing pathological lung damage. In conclusion, the present study not only elucidated the specific anti-inflammatory mechanism of Hes, but also developed a novel composite nanodelivery system by integrating the merits of sIVs and liposomes, thereby providing a promising potential therapeutic strategy for ALI.
如何引用
AMA
Bichao Lu, Jie Su, Yu Long, Xuefeng Liu, Tongfei Fu, Ningfeng Mao, et al. Small intracellular vesicle-liposome fusogenic nanoplatform sIVs-LPs@Hes: Nebulized delivery targeting pulmonary inflammatory microenvironment to improve ALI.. Materials today. Bio. 2026; doi:10.1016/j.mtbio.2026.103305.
APA
Bichao Lu, Jie Su, Yu Long, Xuefeng Liu, Tongfei Fu, Ningfeng Mao, et al (2026). Small intracellular vesicle-liposome fusogenic nanoplatform sIVs-LPs@Hes: Nebulized delivery targeting pulmonary inflammatory microenvironment to improve ALI.. Materials today. Bio. https://doi.org/10.1016/j.mtbio.2026.103305
GB/T 7714
Bichao Lu, Jie Su, Yu Long, Xuefeng Liu, Tongfei Fu, Ningfeng Mao, et al. Small intracellular vesicle-liposome fusogenic nanoplatform sIVs-LPs@Hes: Nebulized delivery targeting pulmonary inflammatory microenvironment to improve ALI.[J]. Materials today. Bio, 2026 doi:10.1016/j.mtbio.2026.103305.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出